What Are Induced Pluripotent Stem Cells (iPSCs), and Why Do They Matter?

WHAT THIS ARTICLE COVERS

Induced pluripotent stem cells, or iPSCs, are ordinary adult cells — often taken from a simple blood draw or skin sample — that scientists reprogram in the lab to behave like the master cells found in a days-old embryo. The discovery that this reprogramming was even possible won a Nobel Prize and effectively created a new branch of biology. This article explains what pluripotency means, how the breakthrough happened, how iPSCs differ from embryonic and adult stem cells, where they're being used in research and early clinical trials today, and — just as importantly — what still stands between this technology and everyday medical use.

What "Pluripotent" Actually Means

Every cell in your body started out as one of a small number of "master" cell types capable of becoming almost anything — heart muscle, neurons, skin, bone. Scientists call this property pluripotency: the ability of a single cell to differentiate into virtually any of the roughly 200 cell types found in the human body (though not into a full organism, which would require totipotency). Normally, pluripotent cells exist only briefly, in the earliest stages of embryonic development, before cells commit to specialized roles. Once a cell becomes a skin cell or a neuron, that commitment was long assumed to be permanent and irreversible.

The Discovery That Rewrote the Rules

That assumption began to crack in 1962, when biologist John Gurdon showed that the nucleus from a mature frog intestinal cell, transplanted into an egg, could still direct the development of a normal tadpole — proof that a specialized cell's genetic instructions weren't erased, just switched off. More than four decades later, Japanese physician-scientist Shinya Yamanaka took the idea further and answered the question Gurdon's work had left open: could a mature cell be reprogrammed while staying fully intact, without any egg or embryo at all?

In 2006, Yamanaka's lab tested a set of genes known to be active in embryonic stem cells and found that inserting just four of them — Oct4, Sox2, Klf4, and c-Myc, now known as the "Yamanaka factors" — into an adult mouse skin cell was enough to reset it into an embryonic-like pluripotent state. In 2007, his team and others replicated the feat with human cells. It was a startlingly simple result for something so profound: four genes, delivered to an ordinary cell, could erase its identity and restore its original, unlimited potential.

In 2012, Gurdon and Yamanaka jointly received the Nobel Prize in Physiology or Medicine "for the discovery that mature cells can be reprogrammed to become pluripotent," a recognition of how directly Yamanaka's work built on and completed the question Gurdon had raised fifty years earlier.

How iPSCs Differ From Embryonic and Adult Stem Cells

Embryonic stem cells (ESCs) are naturally pluripotent, but obtaining them requires early-stage embryos, which raises ethical objections that have shaped decades of policy debate and research funding. iPSCs are pluripotent too — functionally very similar to ESCs — but they're manufactured from a patient's own mature cells, sidestepping that embryo-sourcing issue entirely and, when made from a patient's own tissue, offering a genetic match that could reduce rejection risk.

Adult (or somatic) stem cells, like the mesenchymal stem cells found in bone marrow or fat tissue, sit at the opposite end of the spectrum. They are multipotent, not pluripotent — a blood-forming stem cell in bone marrow can become various blood cell types, but it cannot become a neuron or a heart cell. iPSCs are distinct from both: unlike ESCs, they don't require an embryo; unlike adult stem cells, they aren't limited to one tissue lineage.

What iPSCs Are Used For Today

The first and still largest use of iPSCs is research, not treatment. Scientists routinely take skin or blood cells from patients with a given disease, reprogram them into iPSCs, and then coax them into the specific cell type affected by that disease — heart cells, neurons, liver cells — creating a living model of the disease in a dish. This lets researchers study disease mechanisms and screen drug candidates on human cells that would otherwise be nearly impossible to obtain, without ever touching a patient.

Clinically, iPSCs are moving cautiously from bench to bedside. In one closely watched program at Mass General Brigham, launched in 2024 and funded by the NIH's National Institute of Neurological Disorders and Stroke, researchers convert a Parkinson's patient's own blood cells into iPSCs, then into dopamine-producing neurons, for transplantation back into that same patient's brain — an autologous approach designed to avoid the need for immunosuppression. Separately, the NIH has run a trial using a patient's own iPSC-derived retinal pigment epithelium cells, grown into a thin patch, to treat geographic atrophy, the advanced "dry" form of age-related macular degeneration that currently has no approved treatment. In cancer research, scientists are also exploring iPSC-derived, "off-the-shelf" natural killer (CAR-NK) and T cells engineered to attack tumors, an approach that could someday offer standardized, donor-independent immune cell therapies rather than treatments custom-built for each patient.

Real Risks and Current Limitations

None of this should be mistaken for an approved cure. The reprogramming process itself is the source of real safety concerns. Reprogrammed cells can carry chromosomal abnormalities and other genomic changes acquired during the process, and one of the original Yamanaka factors, c-Myc, is a known proto-oncogene implicated in various cancers. If even a small number of undifferentiated, still-pluripotent iPSCs remain in a final cell product, they carry the potential to form teratomas — tumors made of disorganized tissue — after transplantation. Manufacturing iPSC-derived cells at the purity, scale, and consistency needed for medical use is also technically demanding and expensive. For these reasons, the overwhelming majority of iPSC applications remain investigational: they are being tested in early-phase clinical trials for safety, not yet approved by the FDA as standard treatments, and years of further study stand between today's promising trial results and a therapy your doctor could prescribe.

What the Future Might Look Like

If the safety and manufacturing challenges are solved, iPSCs could eventually enable personalized cell replacement therapies for conditions like Parkinson's disease and macular degeneration, patient-specific disease models that speed up drug development, and standardized immune cell therapies for cancer that don't require a matched donor. That future is not guaranteed on any particular timeline, but the scientific foundation — a Nobel Prize-winning discovery that a cell's fate can be reversed — is now nearly two decades old and has held up to extensive scrutiny.

Bottom Line

iPSC technology represents one of the most significant discoveries in modern biology: proof that mature, specialized cells can be reset to a blank, pluripotent state using just a handful of genes, without embryos. That discovery has already transformed disease research and drug screening, and it is now cautiously entering early-phase human trials for conditions like Parkinson's disease and macular degeneration. But the same reprogramming process that makes iPSCs so powerful also introduces real risks — genomic instability and tumor formation chief among them — and nearly all iPSC-based treatments remain experimental, not FDA-approved. The story so far is one of genuine scientific promise paired with genuine, unresolved caution.